This analysis demonstrates value and innovation of direct-acting antivirals for the treatment of chronic hepatitis C in the US Kaiser Permanente health system.
Fadoua El Moustaid, PhD
Advertisement
Articles by Fadoua El Moustaid, PhD
Advertisement
Latest Updated Articles
Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern CaliforniaPublished: October 20th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Trust and Transparency Key for Leveraging AI to Expand Access to Precision Oncology
2
Executive Order on Homelessness Includes Several Policy Shifts: Katherine Koh, MD, MSc
3
Medicare Insulin Savings Model Cuts Costs, Boosts Access, Report Finds
4
Policy Changes, Price Negotiations Challenge Oncology Innovation: Ryan Haumschild, PharmD, MS, MBA, CPEL
5
